Targeted Oncology
Targeted Oncology
Targeted Oncology


Targeted Oncology | Dialogues in Diagnostics
Targeted Oncology | Differential Diagnosis
Targeted Oncology | Case-Base Peer-Perspective

Top Medical News Today

Low-Risk Meningioma Study Adds Clarity to Irradiation Role
Patients with low-risk meningioma had a 3-year progression-free survival (PFS) that modestly exceeded expectations after gross total resection followed by observation, results of a cooperative group trial showed.
Choose Aggressive Treatment for MCL When Appropriate, Expert Says
Brad S. Kahl, MD, sheds light on the distinctive clinical features of MCL.
Furman Advises In CLL: Choose Appropriate Agents and Focus on PFS Endpoint
Richard R. Furman, MD emphasizes that physicians should follow their best independent judgment regarding therapy selection in CLL, regardless of FDA approval.
HER2-Targeting Antibody-Drug Conjugate Shows Promise in Range of Tumor Types
According to phase I data presented at the 2016 ESMO Congress, a novel HER2-targeting antibody-drug conjugate showed promising antitumor activity across multiple tumor types, including HER2-postive breast cancer.
Patients With mCRPC May Benefit From Adding Bone Drugs to Radium-223
Men with bone-metastatic castration-resistant prostate cancer (mCRPC) appeared to derive additional benefits from treatment with radium-223 with concomitant bone-targeted therapies.
View More >


Novel Treatment Strategies Emerging for CLL
Novel Treatment Strategies Emerging for CLL
Jennifer Brown, MD, PhD, director of the CLL Center at the Dana-Farber Cancer Institute and associate professor at Harvard Medical School, discusses the status of targeted therapy agents for the treatment of patients with CLL
Wierda Discusses Current Questions in Frontline CLL Treatment
William G. Wierda, MD, PhD, discusses which groups of CLL patients may benefit from ibrutinib versus chemoimmunotherapy and clinical trials that may provide further clarification.
Blinatumomab Receives FDA Approval for Acute Lymphoblastic Leukemia
Blinatumomab (Blincyto) has received accelerated approval from the FDA for the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
NDA for Neratinib in HER2-Positive Breast Cancer Accepted by FDA
A new drug application (NDA) for neratinib as an extended adjuvant therapy for patients with HER2-positive breast cancer following prior treatment with postoperative trastuzumab (Herceptin) has been accepted by the FDA
FDA Gives Niraparib Fast Track Designation for Ovarian Cancer
Niraparib has been granted a fast track designation by the FDA as a treatment for women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer